Raymond W. Cohen, a director of Kestra Medical Technologies, LTD., recently expanded his equity position in the company by acquiring 10,000 shares of common stock. The director paid approximately $19.98 per share, bringing the total transaction value to $199,800.
The prices paid across the block ranged between $19.82 and $20.02. After this purchase, Cohen's direct ownership in Kestra Medical stands at 50,903 shares.
At the time of the disclosure, Kestra Medical's shares were trading at $18.33, representing a decline of roughly 31% year-to-date, according to InvestingPro data. The trade therefore occurred at a premium to the current trading level.
Earnings context
Kestra Medical reported results for its fiscal third quarter that contained mixed signals for investors. The company recorded an earnings per share (EPS) loss of -$0.61, which fell short of the consensus forecast of -$0.42. In contrast, reported revenue came in nearly 7% above expectations, reflecting top-line strength.
Analyst feedback following the quarter has been supportive. Piper Sandler reiterated an Overweight rating and set a $30.00 price target, citing the company's robust gross margin performance and an adjusted EBITDA loss that was better than expected. BTIG also maintained a Buy rating with a $32.00 price target and has scheduled virtual investor meetings featuring the company's senior leadership, including President and CEO Brian Webster.
What this means
The director's purchase and the analyst follow-through underline continued market and insider attention on Kestra Medical despite the EPS miss. Revenue outperformance and analysts' comments on margin and adjusted EBITDA drove maintained positive ratings and mid-term price targets from the two firms noted.
Taken together, the transaction and the quarter's results present a picture of mixed near-term profitability metrics but revenue momentum and sustained analyst interest.